156 related articles for article (PubMed ID: 24900278)
1. Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB.
Nakayama M; Yamada S; Ohsawa F; Ohta Y; Kawata K; Makishima M; Kakuta H
ACS Med Chem Lett; 2011 Dec; 2(12):896-900. PubMed ID: 24900278
[TBL] [Abstract][Full Text] [Related]
2. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
Takamatsu K; Takano A; Yakushiji N; Morohashi K; Morishita K; Matsuura N; Makishima M; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 May; 3(5):780-7. PubMed ID: 18297677
[TBL] [Abstract][Full Text] [Related]
3. RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects.
Kawata K; Morishita K; Nakayama M; Yamada S; Kobayashi T; Furusawa Y; Arimoto-Kobayashi S; Oohashi T; Makishima M; Naitou H; Ishitsubo E; Tokiwa H; Tai A; Kakuta H
J Med Chem; 2015 Jan; 58(2):912-26. PubMed ID: 25486327
[TBL] [Abstract][Full Text] [Related]
4. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
Kobayashi T; Furusawa Y; Yamada S; Akehi M; Takenaka F; Sasaki T; Akahoshi A; Hanada T; Matsuura E; Hirano H; Tai A; Kakuta H
ACS Med Chem Lett; 2015 Mar; 6(3):334-8. PubMed ID: 25815156
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats.
Ogasawara A; Murakami Y; Yakushiji N; Ohsawa F; Kusaba J; Aiba T; Kurosaki Y; Kakuta H
Drug Dev Ind Pharm; 2011 Sep; 37(9):1060-7. PubMed ID: 21417609
[TBL] [Abstract][Full Text] [Related]
7. A Retinoid X Receptor Agonist Directed to the Large Intestine Ameliorates T-Cell-Mediated Colitis in Mice.
Matsumoto R; Takahashi D; Watanabe M; Nakatani S; Takamura Y; Kurosaki Y; Kakuta H; Hase K
Front Pharmacol; 2021; 12():715752. PubMed ID: 34475823
[TBL] [Abstract][Full Text] [Related]
8. Development of Scaled-Up Synthetic Method for Retinoid X Receptor Agonist NEt-3IB Contributing to Sustainable Development Goals.
Takamura Y; Morishita KI; Kikuzawa S; Watanabe M; Kakuta H
Chem Pharm Bull (Tokyo); 2022; 70(2):146-154. PubMed ID: 35110435
[TBL] [Abstract][Full Text] [Related]
9. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
10. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
Yamamoto A; Kakuta H; Sugimoto Y
Int Immunopharmacol; 2014 Sep; 22(1):204-8. PubMed ID: 24975659
[TBL] [Abstract][Full Text] [Related]
11. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
12. Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343.
Yukawa-Takamatsu K; Wang Y; Watanabe M; Takamura Y; Fujihara M; Nakamura-Nakayama M; Yamada S; Kikuzawa S; Makishima M; Kawasaki M; Ito S; Nakano S; Kakuta H
J Med Chem; 2021 Jan; 64(1):861-870. PubMed ID: 33378197
[TBL] [Abstract][Full Text] [Related]
13. [Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor].
Kakuta H
Yakugaku Zasshi; 2011; 131(6):917-23. PubMed ID: 21628978
[TBL] [Abstract][Full Text] [Related]
14. Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
Ohsawa F; Morishita K; Yamada S; Makishima M; Kakuta H
ACS Med Chem Lett; 2010 Dec; 1(9):521-5. PubMed ID: 24900241
[TBL] [Abstract][Full Text] [Related]
15. Interspecies comparison of hepatic metabolism of six newly synthesized retinoid X receptor agonistic compounds possessing a 6-[N-ethyl-N-(alkoxyisopropylphenyl)amino]nicotinic acid skeleton in rat and human liver microsomes.
Murakami Y; Shimizu Y; Ogasawara A; Ueshima S; Nakayama M; Kawata K; Kakuta H; Aiba T
Drug Dev Ind Pharm; 2014 Aug; 40(8):1065-71. PubMed ID: 23781857
[TBL] [Abstract][Full Text] [Related]
16. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
[TBL] [Abstract][Full Text] [Related]
17. Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor.
Vu-Dac N; Schoonjans K; Kosykh V; Dallongeville J; Heyman RA; Staels B; Auwerx J
Mol Cell Biol; 1996 Jul; 16(7):3350-60. PubMed ID: 8668150
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
Ohsawa F; Yamada S; Yakushiji N; Shinozaki R; Nakayama M; Kawata K; Hagaya M; Kobayashi T; Kohara K; Furusawa Y; Fujiwara C; Ohta Y; Makishima M; Naitou H; Tai A; Yoshikawa Y; Yasui H; Kakuta H
J Med Chem; 2013 Mar; 56(5):1865-77. PubMed ID: 23391145
[TBL] [Abstract][Full Text] [Related]
19. Retinoid X receptor (RXR) agonist-induced activation of dominant-negative RXR-retinoic acid receptor alpha403 heterodimers is developmentally regulated during myeloid differentiation.
Johnson BS; Chandraratna RA; Heyman RA; Allegretto EA; Mueller L; Collins SJ
Mol Cell Biol; 1999 May; 19(5):3372-82. PubMed ID: 10207061
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent retinoid X receptor ligands for fluorescence polarization assay.
Yamada S; Ohsawa F; Fujii S; Shinozaki R; Makishima M; Naitou H; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5143-6. PubMed ID: 20667726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
